Le Lézard
Classified in: Health, Science and technology
Subject: Award

Amber Salzman, Ph.D., CEO of Epic Bio, Recognized by Endpoints News as One of the Most Influential Women in Biopharma R&D


EPIC BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that Amber Salzman, Ph.D., chief executive officer of Epic Bio, was selected as one of 20 influential women in biopharma by Endpoints News. She will additionally be featured in Endpoints' Women in Biopharma 2022 special report.

"I am honored to be selected as one of Endpoints' influential women blazing trails in biopharma, but my success would not have been possible without the Epic Bio team and the many people who supported and mentored me through my journey. The company has made tremendous progress since 2021 to develop our gene expression modulation platform, or GEMS, and build out our pipeline of therapeutics for monogenic and polygenic diseases," said Amber Salzman, Ph.D. "In addition, we have built a culture of diversity and inclusivity at Epic that enhances our ability to innovate. We continue to provide a space to nurture talent and improve patients' lives."

Each year, Endpoints News selects 20 women in biotech to be honored as trailblazers in biopharma R&D. The list features scientists, CEOs, researchers, and professors who have contributed immensely to the discovery and development of novel therapeutics. Amber has contributed heavily to the field of gene therapy, notably for her work spearheading the development of an experimental gene therapy to treat the deadly neurodegenerative disease adrenoleukodystrophy (ALD). She has also been an advocate for ALD patients and founded the Stop ALD Foundation to accelerate research on the disease.

About Epic Bio

Epic Bio is a leading epigenomic engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company's library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn.


These press releases may also interest you

at 14:00
Yesterday, at a ceremony during SPIE Photonics West, Swave Photonics ? with their Holographic eXtended Reality chips based on proprietary diffractive photonics technology ? was announced the winner of the $10,000 top prize at the 13th annual SPIE...

at 14:00
PetDx® ? The Liquid Biopsy Company for Petstm published a study today describing the optimal age to begin cancer screening for dogs in PLOS ONE, a peer-reviewed open-access scientific journal from the Public Library of Science....

at 14:00
Healthie today announced that it has been named to the New York Digital Health 100 (DH100), a recognition that highlights the most exciting and innovative startups in the New York region.http://dhny.coDigital Health New York (DHNY) publishes the...

at 13:58
Tyber Medical LLC has acquired 100 percent of the capital of ADSM-Synchro Medical, a French orthopedic medical device company, specializing in the development and distribution of implants dedicated to treating surgical forefoot pathologies. Founded...

at 13:50
The "Global CBD Pet Market (2022-2027) by Type, Animal Type, Distribution Channel, and Geography, with Competitive Analysis, Impact of COVID-19, and Ansoff Analysis" report has been added to  ResearchAndMarkets.com's offering. The Global CBD Pet...

at 13:36
Canadian Blood Services is hosting a three-day pop-up barber shop event to raise awareness about the need for stem cell donors and help interested individuals register to become stem cell donors. The event will encourage young males between the ages...



News published on 7 december 2022 at 09:15 and distributed by: